Conferences - Results from #100

ASCO GU 2025: Kidney-Sparing Approach for Selected Localized High-Risk Upper Tract Urothelial Carcinoma: A Pilot Study Combining Endoscopic Thulium Laser Ablation With Perioperative Disitamab Vedotin and Immune Checkpoint Inhibitors February 15, 2025

ASCO GU 2025: The Impact of Salvage Therapies: Functional Outcomes and Quality of Life February 15, 2025

ASCO GU 2025: Real-World Analysis of the Efficacy and Safety of Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study February 14, 2025

ASCO GU 2025: Global Real-World Patients Characteristics, Treatment Patterns, and Impact of BCG Shortage in Patients with High-Risk Non-Muscle Invasive Bladder Cancer February 14, 2025

ASCO GU 2025: Neoadjuvant Treatment with Disitamab Vedotin plus Perioperative Toripalimab in Patients with MIBC with HER2 Expression: Updated Efficacy and Safety Results from the Phase II RC48-C017 Trial February 14, 2025

ASCO GU 2025: Adjuvant Nivolumab vs Placebo for High-Risk Muscle-Invasive Urothelial Carcinoma: Additional Efficacy Outcomes Including Overall Survival in Patients with MIBC from CheckMate 274 February 14, 2025

ASCO GU 2025: iNDUCT: Safety and Efficacy of Neoadjuvant Immunotherapy with Durvalumab in Combination with Neoadjuvant Chemotherapy (Gemcitabine/cisplatin or Carboplatin) in Patients with Operable High-Risk Upper Tract Urothelial Carcinoma February 14, 2025

ASCO GU 2025: Phase II Study of Oral APL-1202 plus Tislelizumab or Tislelizumab Alone as Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer (MIBC) February 14, 2025

ASCO GU 2025: Phase Ib/II Clinical Trial of Oncolytic Virus Intravesical Irrigation for Preventing Recurrence After TURBT in Patients with Recurrent High-Risk NMIBC February 14, 2025

ASCO GU 2025: The Changing World of Non-Muscle-Invasive Bladder Cancer February 14, 2025

ASCO GU 2025: Postoperative Adjuvant Treatment of HER2 Overexpression in Upper Urinary Tract Urothelial Carcinoma with the Combination of Disitamab Vedotin and Toripalimab: A Real-World Retrospective Study. February 14, 2025

ASCO GU 2025: A Heterologous Prime-Boost Strategy Using RUTI Vaccine to Improve the BCG Response in Non–muscle-Invasive Bladder Cancer Patients (RUTIVAC-1 Trial) February 14, 2025

ASCO GU 2025: Evaluating Survival in Aggressive Variant Prostate Cancer Patients Undergoing PSMA Radioligand Therapy February 14, 2025

ASCO GU 2025: The Prognostic Impact of Prostate-Specific Antigen at 6 Months After Post-Prostatectomy Radiotherapy: An Individual Patient Data Analysis of Two NRG Oncology Randomized Trials February 14, 2025

ASCO GU 2025: World-Wide Oligometastatic Prostate Cancer (omPC) Meta-Analysis Leveraging Individual Patient Data (IPD) from Randomized Trials (WOLVERINE): An Analysis from the X-MET Collaboration February 14, 2025

ASCO GU 2025: Real-World Effectiveness and Safety of Avelumab First-Line Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Carcinoma: Second Interim Analysis of the AVENUE Study. February 14, 2025

ASCO GU 2025: Gene Expression Signatures of Immune Infiltration Portend Differential Response to Gem/Doce Versus BCG in High-Risk Non-Muscle-Invasive Bladder Cancer February 14, 2025

ASCO GU 2025: EORTC GUCG 2418 - STARBURST: Strategies for Treatment Adaptation Following Re-Evaluation of the Bladder After Using Primary Neoadjuvant Systemic therapies—An EORTC Platform Trial February 14, 2025

ASCO GU 2025: Upstaging and Risk Migration With Blue Light Cystoscopy for Non–Muscle-Invasive Bladder Cancer: Results From a Prospective Multi-Center Registry February 14, 2025

ASCO GU 2025: Outcomes of Enfortumab Vedotin and Pembrolizumab for Patients Previously Treated with Immune Checkpoint Inhibitors in the UNITE Study. February 14, 2025

Page 6 of 606